S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Inclusion Criteria:

* Histological or cytologically confirmed small cell lung cancer;
* Systemic chemotherapy that has previously received at least one or more lines regimen, followed by disease progression or recurrence;
* Age 18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months
* participants had at least one measurable target lesion by RECIST1.1
* The main organ function meets the following criteria:absolute value of neutrophils ≥ 1.5 × 109 / L, platelets ≥80 × 109 / L, hemoglobin ≥ 80 g / L;total bilirubin ≤ 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal value (if liver metastasis, ≤ upper limit of normal value 5 times), serum creatinine ≤ 1.5 times the upper limit of normal;
* Patients should participate in the study voluntarily and sign informed consent

Exclusion Criteria:

* Patients who have been used anti-angiogenesis inhibitors,such as (such as sunitinib,bevacizumab,endostar et al.
* Subjects with symptomatic brain metastases;
* Patients whose primary lesion with active bleeding within 4 months
* Hypertension, which is uncontrolled by the drug, is defined as: systolic blood pressure ≥ 160 mmHg, or diastolic blood pressure ≥ 100 mmHg
* Patients with active or unable to control serious infections
* Patients who are pregnant or breastfeeding.